Funder
NCI
Burroughs Wellcome Fund
National Center for Advancing Translational Sciences
Yale Cancer Center
Cepheid
National Institutes of Health
Subject
Pathology and Forensic Medicine
Reference17 articles.
1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J Immunother Cancer,2018
2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012
3. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013
4. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial;Fuchs;JAMA Oncol,2018
5. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors;Davis;J Immunother Cancer,2019
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献